Advancing Subcutaneous Diuretic Therapy for Heart Failure Management

Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Marking under the EU Medical Device Regulation and has been accepted by the European Medicines Agency (EMA) for review. These milestones clear a path toward pan-European availability of an innovative subcutaneous diuretic therapy that delivers intravenous-like diuresis while allowing patients to treat fluid overload safely at home.

Shifting from Hospital to Home

The most significant insight from this development is the potential to break the cycle of repeated hospitalizations by moving effective diuresis out of the hospital. Edema remains one of the top reasons elderly heart failure patients are admitted across Europe and the United States. Lasix ONYU administers 80 mg of furosemide (30 mg/mL in a 2.67 mL cartridge) over five hours via a wearable, two-part electromechanical infusor. This slow subcutaneous infusion achieves substantial fluid removal comparable to intravenous furosemide, yet avoids the abrupt diuresis associated with rapid IV delivery. By enabling reliable at-home treatment, subcutaneous diuretic therapy offers meaningful gains in patient convenience, quality of life, and reduced healthcare system burden.

Regulatory Breakthroughs Pave the Way

CE Marking confirms that the Lasix ONYU Infusor meets the stringent General Safety and Performance Requirements of the EU MDR 2017/745. Simultaneously, the EMA has accepted the product for evaluation under the centralized procedure on the basis of technical innovation, recognizing its potential to address a major unmet need. These dual achievements, which follow U.S. FDA approval in October 2025, provide a strong foundation for pan-European marketing authorization expected after submission of the Market Authorization Application later in 2026. Learn more

Economic Value and Market Access Implications

By replacing hospital-based intravenous treatment with effective at-home subcutaneous diuretic therapy, Lasix ONYU has strong potential to improve cost-effectiveness through shorter hospital stays, fewer readmissions, and lower overall episode costs. Health economics and outcomes research teams are expected to focus on real-world evidence that demonstrates clinical equivalence to IV furosemide alongside superior patient-reported outcomes in quality of life and treatment convenience. The EMA’s technical innovation designation may also open doors to constructive early dialogue with health technology assessment bodies, supporting value-based pricing discussions.

Payers will scrutinize budget-impact models that weigh the device cost against downstream savings from avoided admissions. The product’s reusable electromechanical component and reduced waste profile further align with growing green procurement priorities in European health systems.